Clinical Trials

Colorectal Neoplasms

NCT05343013 2026-03-06

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

25 enrolled

Colorectal Neoplasms

NCT04511039 2026-03-02

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Phase 1 Recruiting

45 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Colorectal Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

Phase 3 Completed

563 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07361003 2026-01-22

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

Phase 3 Recruiting

464 enrolled

Colorectal Neoplasms

NCT03844620 2026-01-09

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

100 enrolled

Phase 3 Active not recruiting

Colorectal Neoplasms

NCT03869892 2025-12-22

SOLSTICE

856 enrolled

Phase 1 Active not recruiting

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT04104139 2025-10-27

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

19 enrolled

Rectal Neoplasms

NCT07212933 2025-10-08

RAK in GC

90 enrolled

Stomach Neoplasms

NCT07085169 2025-07-25

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

50 enrolled

Phase 3 Active not recruiting

Colonic Neoplasms

NCT04879368 2025-07-17

INTEGRATEIIb

450 enrolled

Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT05508737 2025-07-11

Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Phase 1/2 Active not recruiting

75 enrolled

Gastric and Gastroesophageal Junction Adenocarcinoma

NCT06873763 2025-07-11

Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

Phase 1/2 Recruiting

52 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT05201352 2025-05-30

TASKIN

160 enrolled

Colorectal Neoplasms

NCT04920032 2025-04-08

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Phase 1 Recruiting

22 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT04450836 2025-03-30

SOREGATT

Phase 2 Terminated

234 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT06882915 2025-03-19

Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

20 enrolled

Phase 2 Not yet recruiting

Colorectal Neoplasms

NCT06872606 2025-03-12

SCRIPBOT

33 enrolled

Phase 1/2 Active not recruiting

Rectal Neoplasms

NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

64 enrolled

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06711471 2024-12-02

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

31 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT04294264 2024-11-18

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

50 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06403709 2024-09-24

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

35 enrolled

Colorectal Neoplasms

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01867866 2024-09-05

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

44 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03981614 2024-08-22

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Phase 2 Completed

102 enrolled 11 charts

Colorectal Neoplasms

NCT05130060 2024-08-14

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

15 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02848443 2024-07-25

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

78 enrolled

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT03306394 2024-07-25

PRECONNECT

Phase 3 Completed

907 enrolled

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT06485713 2024-07-03

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

200 enrolled

Colorectal Neoplasms

NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

12 enrolled 16 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03317119 2024-04-08

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

26 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06202001 2024-04-02

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Phase 1/2 Recruiting

70 enrolled

Colorectal Neoplasms

NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

116 enrolled

Clinical Stage III Gastric Cancer AJCC v8

NCT06293014 2024-03-05

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

224 enrolled

Colorectal Neoplasms

NCT05007132 2024-02-15

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

153 enrolled

Colorectal Neoplasms

NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

20 enrolled 9 charts

Gastric Adenocarcinoma

NCT04854434 2023-11-03

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Phase 2 Terminated

13 enrolled 14 charts

Colorectal Neoplasms

NCT04072445 2023-08-09

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Phase 2 Completed

28 enrolled 20 charts

Bile Duct Neoplasms, Gallbladder Neoplasms

NCT04177602 2023-02-22

Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial

Phase 1/2 Terminated

10 enrolled

Rectal Neoplasms

NCT03974594 2022-04-19

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

64 enrolled